Direct oral anticoagulants in frail older adults: A geriatric perspective

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 4, 2015, Pages 389-394

  Ho, Prahlad ^a   Brooy, Beth La ^a   Hayes, Lachlan ^a   Lim, Wen Kwang ^a  

^a NORTHERN HOSPITAL   (Australia)

Author keywords

bleeding; direct oral anticoagulants; frailty; older adults

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGED; ALGORITHM; ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; COMORBIDITY; FRAIL ELDERLY; GERIATRICS; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; DRUG MONITORING; ELDERLY CARE; FALLING; HEMORRHAGE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACCIDENTAL FALLS; ADMINISTRATION, ORAL; ADULT; AGED; ALGORITHMS; ANTICOAGULANTS; DRUG MONITORING; HEALTH SERVICES FOR THE AGED; HEMORRHAGE; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84930374812     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1550158     Document Type: Article

References (44)

1. Hankey G. J. Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned? Curr Cardiol Rep: 2014; 16 5 480
2. Breithardt G., Baumgartner H., Berkowitz S. D., et al. ROCKET AF Steering Committee & Investigators. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J: 2014; 35 47 3377 3385
3. Connolly S. J., Wallentin L., Ezekowitz M. D., et al. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation: 2013; 128 3 237 243
4. Granger C. B., Lopes R. D., Hanna M., et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J: 2015; 169 1 25 30
5. Agnelli G., Buller H. R., Cohen A., et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med: 2013; 369 9 799 808
6. Prins M. H., Lensing A. W., Bauersachs R., et al. EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J: 2013; 11 1 21
7. Ma T. K., Yan B. P., Lam Y. Y. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data. Pharmacol Ther: 2011; 129 2 185 194
8. Cuker A., Siegal D. M., Crowther M. A., Garcia D. A. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol: 2014; 64 11 1128 1139
9. van Ryn J., Stangier J., Haertter S., et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost: 2010; 103 6 1116 1127
10. Frost C., Nepal S., Wang J., et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol: 2013; 76 5 776 786
11. Kubitza D., Becka M., Voith B., Zuehlsdorf M., Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther: 2005; 78 4 412 421
12. Sardar P., Chatterjee S., Chaudhari S., Lip G. Y. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc: 2014; 62 5 857 864
13. Coppens M., Synhorst D., Eikelboom J. W., Yusuf S., Shestakovska O., Connolly S. J. Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. Eur Heart J: 2014; 35 28 1856 1863
14. Gomes T., Mamdani M. M., Holbrook A. M., Paterson J. M., Hellings C., Juurlink D. N. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ: 2013; 185 2 E121 E127
15. Tran H., Joseph J., Young L., et al. Australasian Society of Thrombosis and Haemostasis. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Intern Med J: 2014; 44 6 525 536
16. Cohen A. T., Spiro T. E., Büller H. R., et al. MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med: 2013; 368 6 513 523
17. Lambourne M. D., Eltringham-Smith L. J., Gataiance S., Arnold D. M., Crowther M. A., Sheffield W. P. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost: 2012; 10 9 1830 1840
18. Pragst I., Zeitler S. H., Doerr B., et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost: 2012; 10 9 1841 1848
19. Marlu R., Hodaj E., Paris A., Albaladejo P., Cracowski J. L., Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost: 2012; 108 2 217 224
20. Eerenberg E. S., Kamphuisen P. W., Sijpkens M. K., Meijers J. C., Buller H. R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation: 2011; 124 14 1573 1579
21. van Ryn J. RD, Priepke H., Hauel N., Wienen W. Reversibility of the anticoagulant effect of high doses of direct thrombin inhibitor, dabiagtran, but recombnant activated factor VIIa or activated prothrombin complex. Presented at: 13th Congress of the European Haematology Association; Copenhagen, Denmark: Haematologica; 2008:148
22. Ho W. K., Hankey G. J., Eikelboom J. W. The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. Med J Aust: 2008; 189 3 144 147
23. Lip G. Y., Nieuwlaat R., Pisters R., Lane D. A., Crijns H. J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest: 2010; 137 2 263 272
24. Rockwood P. R., Horne J. G., Cryer C. Hip fractures: a future epidemic? J Orthop Trauma: 1990; 4 4 388 393
25. Morley J. E., Vellas B., van Kan G. A., et al. Frailty consensus: a call to action. J Am Med Dir Assoc: 2013; 14 6 392 397
26. Rockwood K., Song X., MacKnight C., et al. A global clinical measure of fitness and frailty in elderly people. CMAJ: 2005; 173 5 489 495
27. Hubbard R. E., O'Mahony M. S., Woodhouse K. W. Medication prescribing in frail older people. Eur J Clin Pharmacol: 2013; 69 3 319 326
28. Collard R. M., Boter H., Schoevers R. A., Oude Voshaar R. C. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc: 2012; 60 8 1487 1492
29. Fried L. P., Tangen C. M., Walston J., et al. Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci: 2001; 56 3 M146 M156
30. Frey P. M., Méan M., Limacher A., et al. Physical activity and risk of bleeding in elderly patients taking anticoagulants. J Thromb Haemost: 2015; 13 2 197 205
31. Watts G. Why the exclusion of older people from clinical research must stop. BMJ: 2012; 344 e3445. doi: 10.1136/bmj.e3445
32. Van Spall H. G., Toren A., Kiss A., Fowler R. A. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA: 2007; 297 11 1233 1240
33. Mitnitski A. B., Mogilner A. J., Rockwood K. Accumulation of deficits as a proxy measure of aging. ScientificWorldJournal: 2001; 1 323 336
34. Morley J. E., Malmstrom T. K., Miller D. K. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging: 2012; 16 7 601 608
35. Lopez D., Flicker L., Dobson A. Validation of the frail scale in a cohort of older Australian women. J Am Geriatr Soc: 2012; 60 1 171 173
36. Subra J., Gillette-Guyonnet S., Cesari M., Oustric S., Vellas B.; Platform Team. The integration of frailty into clinical practice: preliminary results from the Gérontopôle. J Nutr Health Aging: 2012; 16 8 714 720
37. Sujino Y., Tanno J., Nakano S., et al. Impact of hypoalbuminemia, frailty, and body mass index on early prognosis in older patients (≥85 years) with ST-elevation myocardial infarctions (epub ahead of print). J Cardiol: 2014
38. Jung P., Pereira M. A., Hiebert B., et al. The impact of frailty on postoperative delirium in cardiac surgery patients. J Thorac Cardiovasc Surg: 2015; 149 3 869 875
39. Goldstein J., Hubbard R. E., Moorhouse P., Andrew M. K., Mitnitski A., Rockwood K. The validation of a care partner-derived frailty index based upon comprehensive geriatric assessment (CP-FI-CGA) in emergency medical services and geriatric ambulatory care. Age Ageing: 2015; 44 2 327 330
40. Coresh J., Selvin E., Stevens L. A., et al. Prevalence of chronic kidney disease in the United States. JAMA: 2007; 298 17 2038 2047
41. Anderson S., Halter J. B., Hazzard W. R., et al. workshop participants. Prediction, progression, and outcomes of chronic kidney disease in older adults. J Am Soc Nephrol: 2009; 20 6 1199 1209
42. Pather M. The prevalence of renal impairment in the elderly hospitalized population. Int J Gen Med: 2009; 2 117 119
43. Lane D. A., Lip G. Y. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation: 2012; 126 7 860 865
44. Pisters R., Lane D. A., Nieuwlaat R., de Vos C. B., Crijns H. J., Lip G. Y. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest: 2010; 138 5 1093 1100